Fc Variant Antibody Selection for Polymorphism-Based Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody therapies, such as rituximab, face challenges in predicting patient responsiveness due to unclear mechanisms of action and resistance, leading to delayed alternative treatments, adverse effects, and unnecessary expenses.
Innovation Solution
Genotyping patients for FcγRIIA and FcγRIIIA polymorphisms to determine their responsiveness to antibody therapies, allowing for the selection of specific Fc variant antibodies that enhance binding affinity and ADCC function, thereby improving treatment outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibody therapy is administered to all patients regardless of responsiveness, then treatment coverage is maximized, but adverse effects and unnecessary expenses increase
Solution Approach 1:
The patent applies preliminary action by performing genotyping analysis of FcγRIIA and FcγRIIIA polymorphisms before administering antibody therapy. This preliminary genetic characterization allows clinicians to predict patient responsiveness and select appropriate therapies in advance, preventing adverse effects and unnecessary treatments before they occur.
Solution Approach 2:
The patent applies local quality by customizing antibody therapy based on individual patient genetic characteristics. Different Fc variant antibodies are selected for different patient groups based on their specific FcγR polymorphism profiles, rather than using a uniform treatment approach for all patients.
2Ease of operation
If standard antibody therapy is used for all patients, then treatment simplicity is maintained, but treatment response varies significantly due to genetic differences
Solution Approach 1:
The patent implements local quality by tailoring antibody therapy to match specific patient genetic subgroups. Patients are categorized based on their FcγRIIA and FcγRIIIA polymorphism profiles, and Fc variant antibodies are selectively assigned to optimize treatment response for each genetic group.
Solution Approach 2:
The patent applies parameter changes by modifying the Fc region characteristics of antibodies to match patient genetic profiles. Different Fc variant antibodies with optimized binding affinities for specific FcγR polymorphisms are selected based on patient genotyping results, thereby adjusting treatment parameters to patient-specific genetic parameters.
3Measurement precision
If Fc variant antibodies are developed for different genetic groups, then treatment precision is improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the patient population into distinct genetic subgroups based on FcγRIIA and FcγRIIIA polymorphisms. This segmentation enables the development and deployment of specific Fc variant antibodies for each subgroup, improving treatment precision while managing complexity through systematic categorization.
4Reliability
If genotyping is performed for all patients, then treatment personalization is achieved, but diagnostic time and cost increase
Solution Approach 1:
The patent applies preliminary action by performing genotyping analysis before treatment initiation to predict responsiveness and guide therapy selection. This advance genetic characterization prevents time loss during treatment by establishing the appropriate therapeutic approach beforehand.
Data Source
AI summary
Methods and materials are provided for determining the responsiveness of a subject to a therapy, such as an antibody therapy and for selecting and/or for treating a subject based on a FcγRIIA polymorphism, or a FcγRIIIA polymorphism, or both an FcγRIIA polymorphism and a FcγRIIIA polymorphism, including where the treatment is an therapy, such as rituximab. Methods and materials are also provided for designing, making, screening, testing and/or administering antibodies as well as for optimizing antibody therapies based upon a subject's FcγRIIA polymorphism, or FcγRIIIA polymorphism, or both the FcγRIIA polymorphism and the FcγRIIIA polymorphism.